XOMA Corporation (XOMA)

[beambe]

$32 million cash at September 30, 2015
? Raised ~$50.5 million non-dilutive liquidity by licensing TGFß antibody
program to Novartis on September 30, 2015
• $37 million upfront payment received in October
• $13.5 million loan maturity date extended to September 2020
• Potential milestone payments of up to $480 million
• Royalties tiered from mid-single digits to low double digits
? Raised $5.0 million by licensing XMetA program to Novo Nordisk on
December 1, 2015
• $5 million upfront payment
• Potential milestone payments of up to $290 million
• Royalties tiered from mid- to high-single digits
? Corporate actions reduces cash burn rate significantly
• Restructured and reduced employee base by 50%
• Appropriately sized to rapidly advance the endocrine franchise
? Cash runway into 2017
? Approximately 118.8 million shares outstanding at September 30, 2015

http://www.xoma.com/pdf/XOMACorporatePresentation-March2016.pdf